The verdict from ALLHAT - Thiazide diuretics are the preferred initial therapy for hypertension

JAMA

Volumn 288, Issue 23, 2002, Pages 3039-3042

  Appel, Lawrence J ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CHLORTALIDONE; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; ENALAPRIL; HYDRALAZINE; LISINOPRIL; RESERPINE; THIAZIDE DIURETIC AGENT; VASODILATOR AGENT; VERAPAMIL;

ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE CONTROL; DRUG COST; DRUG INDICATION; DYSLIPIDEMIA; EDITORIAL; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; HYPOKALEMIA; INSULIN RESISTANCE; PRIORITY JOURNAL;

EID: 0037132675     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.288.23.3039     Document Type: Editorial

References (21)

1. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
2. Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA. 2002;287:1003-1010.
3. Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med. 2001;345:479-486.
4. Whelton PK, Adams-Campbell LL, Appel LJ, et al. National High Blood Pressure Education Program Working Group report on primary prevention of hypertension. Arch Intern Med. 1993;153:186-208.
5. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease, part 2: Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet. 1990;335:827-838.
6. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease, part 1: Prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765-774.
7. Manolio TA, Cutler JA, Furberg CD, et al. Trends in pharmacologic management of hypertension in the United States. Arch Intern Med. 1999;155;829-837.
8. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with hypertensive drug therapies. JAMA. 1999;274:620-625.
9. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2000;283:1967-1975.
10. Pahor M, Psaty BM, Alderman MH, et al. Health outcomes associated with calcium channel antagonists compared with other first-line antihypertensive therapies: A meta-analysis of randomised controlled trials. Lancet. 2000;356:1949-1954.
11. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials. Lancet. 2000;355:1955-1964.
12. The SOLVD Investigators. Effect of enalapril on morality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685-691.
13. The ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme in hibitors? A meta-analysis of individual patient data. Ann Intern Med. 2001;134:370-379.
14. Jafar TH, Schmid CH, Landa M, et al, for the ACE Inhibition in Progressive Renal Disease Study Group. Review: Angiotensin-converting enzyme inhibitors reduce the progression of nondiabetic renal disease. Ann Intern Med. 2001;135: 73-87.
15. Wright JW, Bakris G, Greene T, et al, for the AASK Collaborative Research Group. Effect of blood pressure lowering and antihypertensive class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA. 2002;288: 2421-2431.
16. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-3264.
17. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents: A systematic review and metaanalysis. JAMA. 1997;277:739-745.
18. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on the prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157:2413-2446.
19. Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med. 1998;339:1957-1963.
20. Chobanian AV. Control of hypertension: An important national priority. N Engl J Med. 2001;345:534-535.
21. Whelton PK, He J, Appel LJ, et al. Primary prevention of hypertension: Clinical and public health advisory from the National High Blood Pressure Education Program. JAMA. 2002;288:1882-1888.